Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTX-A51 alone and with fulvestrant in advanced solid tumors and breast cancer
NCT04872166Phase 1Recruiting
- Sponsor
- Edgewood Oncology
- Start
- Jun 2021
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BTX-A51 in solid tumor (advanced stage) and breast cancer (8 cohorts), sponsored by Edgewood Oncology. Primary endpoints: Incidence of adverse events and Maximum Tolerated Dose or Recommended Phase 2 Dose. Started Jun 2021; status: recruiting.
02
Drugs
BTX-A51
03
Conditions
solid tumor (advanced stage)breast cancer
Beyond the preview
Go deeper on NCT04872166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04872166.